NCT02753192	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02753192","NCT02753192")		2014	Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison	Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison		N/A	Yes	Patients (Other)	Centre National de la Recherche Scientifique, France	Other		Inclusion Criteria: All participants - Age between 35 and 85 years old - Good cooperation - Ability to understand the information sheet - Given signed consent - Affiliation to a medical-social insurance regimen - Other stable medical problems not interfering with the proposed study Only for patients: - Absence of any neurological, psychiatric or behavioral pathology - Idiopathic Parkinson's disease - Absence of medication-induced psychosis, severe depression or dementia 	Exclusion Criteria: All participants - Illiteracy - French/Portuguese not as native language, or bilingual participants - Participant under tutorship or guardianship, or any other administrative or legal measure - No cooperation or withdrawn consent - Cognitive deficits, depression, psychosis or behavioral, neurological, medical, psychological disorders that may interfere with vital prognostic and evaluations Only for patients: - Non-idiopathic Parkinson's disease - (Too) severe motor impairment impeding to participate in the study			120	Anticipated	Unknown status
NCT03764215	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03764215","NCT03764215")		2018	Nilotinib in Huntington's Disease	An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease		1	No	Nilotinib 150 MG (Drug)	Georgetown University	Other		Inclusion Criteria: - Written informed consent - Capable of providing informed consent and complying with study procedures. Subjects who are unable to provide consent may use a Legally Authorized Representative (LAR). - Patients between the age of 25-90 years, medically stable - Clinical diagnosis of HD with either a confirmed family history or positive CAG repeat (CAG≥35) - MoCA ≥ 22 - Able to perform the TMT-B in ≤240 seconds - Total Functional Capacity 7-12 - Stable concomitant medical and/or psychiatric illnesses, in the judgement of the PI. - QTc interval 350-460 ms, inclusive - Participants must be willing to undergo LP at baseline and 3 months after treatment 	Exclusion Criteria: - Patients with hypokalemia, hypomagnesaemia, or long QT syndrome- QTc≥461 ms - Concomitant drugs known to prolong the QTc interval and history of any cardiovascular disease, including myocardial infarction or cardiac failure, angina, arrhythmia - History or presence of cardiac conditions including: 1. Cardiovascular or cerebrovascular event (e.g. myocardial infarction, unstable angina, or stroke) 2. Congestive heart failure 3. First, second- or third-degree atrioventricular block, sick sinus syndrome, or other serious cardiac rhythm disturbances 4. Any history of Torsade de Pointes - Treatment with any of the following drugs at the time of screening or the preceding 30 days, and/or planned use over the course of the trial: 1. Treatment with Class IA or III antiarrhythmic drugs (e.g. quinidine) 2. Treatment with QT prolonging drugs (www.crediblemeds.org)- excluding Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g. Citalopram, Escitalopram, Paroxetine, Sertraline, Duloxetine, Trazodone, etc.) 3. Strong CYP3A4 inhibitors (including grapefruit juice). The concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) must be avoided. Grapefruit products may also increase serum concentrations of Nilotinib. Should treatment with any of these agents be required, therapy with Nilotinib should be interrupted. 4. Anticoagulants, including Coumadin (warfarin), heparin, enoxaparin, daltiparin, xarelto, etc. 5. St. John's Wort and the concomitant use of strong other CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) must be avoided since these agents may reduce the concentration of Nilotinib. - Abnormal liver function defined as AST and/or ALT > 100% the upper limit of the normal - Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal - History of HIV, clinically significant chronic hepatitis, or other active infection - Females must not be lactating, pregnant or with possible pregnancy - Medical history of liver or pancreatic disease - Clinical signs indicating syndromes other than idiopathic PD, including corticobasal degeneration, supranuclear gaze palsy, multiple system atrophy, chronic traumatic encephalopathy, signs of frontal dementia, history of stroke, head injury or encephalitis, cerebellar signs, early severe autonomic involvement, Babinski sign .Current evidence or history in past two years of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any active major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse - Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal or other systemic disease or laboratory abnormality - Active neoplastic disease, history of cancer five years prior to screening, including breast cancer (history of skin melanoma or stable prostate cancer are not exclusionary) - Contraindications to LP: prior lumbosacral spine surgery, severe degenerative joint disease or deformity of the spine, platelets < 100,000, use of Coumadin/warfarin, or history of a bleeding disorder - Must not be on any immunosuppressant medications (e.g. IVig) - Must not be enrolled as an active participant in another clinical study			10	Anticipated	Recruiting
NCT03854019	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03854019","NCT03854019")		2019	Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease	Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease		3	Yes	Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) (Drug); Placebo (Drug)	The University of Texas Health Science Center, Houston	Other		Inclusion Criteria: - Verified HD mutation carriers; - Irritable as diagnosed by the Irritability Scale with a score > 14; - Stable concomitant medication (no change of medication during last 30 days prior to inclusion); - Written informed consent by prospective study participant before conduct of any trial-related procedure. Participant must be able to make an informed decision of whether or not to participate in the study. 	Exclusion Criteria: - Hypersensitivity to dextromethorphan (e.g., rash, hives), quinine, mefloquine, quinidine, or dextromethorphan/quinidine with a history of thrombocytopenia, hepatitis, bone marrow depression or lupus-like syndrome induced by these drugs; - Pregnant or nursing women; - Active suicidality based on the answer "yes" in questions 4 and 5 of the Columbia-Suicide Severity Rating Scale (baseline version); - Woman of childbearing potential, not using highly effective methods of contraception such as oral, topical or injected contraception, IUD, contraceptive vaginal ring, or double barrier method such as diaphragm and condom with spermicide) or not surgically sterile (via hysterectomy, ovarectomy or bilateral tubal ligation) or not at least one year post-menopausal; - Male not using an acceptable barrier method for contraception; - Presence of any medically not controllable disease (e.g. uncontrolled arterial hypertension or diabetes mellitus); - Clinically significant renal (calculated creatinine clearance < 30 ml/min) or hepatic dysfunction; - Patients with pre-existing hepatic disease; - Individuals with a history or complete heart block, QTc prolongation or tornadoes de pointes, or at high risk of complete AV block; - Family history of congenital QT prolongation; - History of unexplained syncope within the past year; - Use of drugs containing quinidine, quinine, or mefloquine; - Individuals currently taking strong CYP3A4 inhibitors or tetrabenazine; - Use of certain antidepressants--amitriptyline, clomipramine, desipramine, fluoxetine, paroxetine, sertraline, venlafaxine; - Use of certain heart rhythm medications--amiodarone, flecainide, procainamide, propafenone; - Use of certain medicines to treat psychiatric disorders--chlorpromazine, haloperidol, perphenazine, pimozide, quetiapine, risperidone, thioridazine. - Use of tamoxifen; - Presence or history of seizures or diagnosed epilepsy; - Severe cognitive disorders defined as a score < 18 on the MOCA; - Clinically relevant abnormal findings in the ECG, the vitals, in the physical examination or laboratory values at screening that could interfere with the objectives of the study or the safety of the subject as judged by the investigator; - Participation in another investigative drug trial within 2 months; - Subjects who are unlikely to be compliant and attend scheduled clinic visits as required as determined by the Investigator.			22	Anticipated	Recruiting
NCT01851850	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01851850","NCT01851850")		2013	Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial	Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial		3	No	Opicapone (Drug)	Rabin Medical Center	Other		Inclusion Criteria: - clinical diagnosis with PD - subjects who are willing to participate in the trial. - subjects who participated in the BIA 9-1067-302 clinical trial. 	Exclusion Criteria: - subjects who didn't take part at the BIA 9-1067-302 clinical trial.			1	Anticipated	Unknown status
NCT02243982	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02243982","NCT02243982")		2010	Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease	Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in Cerebrospinal Fluid and Positron Emission Tomography in the Dementia of Parkinson's Disease		Early 1	Yes	[F18]-FDDNP (Other)	Fundacion Clinic per a la Recerca Biomédica	Other		Inclusion Criteria: Inclusion Criteria PDD - Male or female ≥ 60 years old; - Diagnose of PD probable or definite according to criteria of the United Kingdom Parkinson's Disease Society Brain Bank; - The Hoehn & Yahr stage of the disease between 3 and 5 in off state; - Diagnose of dementia established according to the fourth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and the diagnostic guidelines for dementia of the Movement Disorders Society (MDS); - The score of the Mini-Mental State Examination of Folstein (MMSE) <24; - The score on the Mattis Dementia Rating Scale (MDRS) <136. Inclusion criteria PDND: - Male or female ≥ 60 years old; - Diagnose of PD probable or definite according to criteria of the United Kingdom Parkinson's Disease Society Brain Bank; - The Hoehn & Yahr stage of the disease between 3 and 5 in OFF state; - The score of the Mini-Mental State Examination of Folstein (MMSE) ≥24; - The score on the Mattis Dementia Rating Scale (MDRS) ≥136. Inclusion criteria Controls: - Male or female ≥ 60 years old; - No known diagnosis of neuropsychiatric diseases - The score of the Mini-Mental State Examination of Folstein (MMSE) ≥24; - The score on the Mattis Dementia Rating Scale (MDRS) ≥136. 	Exclusion Criteria: - The subject is pregnant or breastfeeding; - The subject has a history of drug abuse or alcohol; - The subject has developed dementia in the first year of parkinsonism or before than parkinsonism; - The subject meets criteria for vascular dementia; - The subject has symptoms suggestive of other types of parkinsonism (multi-system atrophy cortico-basal, supra-nuclear palsy progressive degeneration) or degenerative dementia (fronto-temporal dementia); - The subject has a moderate or severe renal functional impairment (serum creatinine> 1.5 mg / dL); - The subject has a moderate or severe hepatic impairment (bilirubin> 2 times the upper limit of normal, transaminases> 3 times the upper limit of normal); - The subject presents structural abnormalities in basal ganglia or cortical level on magnetic resonance imaging or computerized tomography; - The subject has participated in a clinical study with an investigational drug product within 30 days prior to screening and / or radiopharmaceutical in a minimum period of 5 radioactive half-lives prior to screening; - Occupational exposure to radiation> 15 milliSievert (mSv) / year - The subject has received treatment with non-steroidal anti-inflammatory drugs during the 30-day period before the PET scan - The subject has allergy to the investigational product or any of its components; - The subject has a clinically active, serious disease with a reduced life expectancy; - The subject is claustrophobic / a. - The subject has received in the last 364 days a dose of ionizing radiation that coupled with the study dose exceeds 10 mSv			28	Actual	Completed
NCT01765257	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01765257","NCT01765257")		2013	Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study	Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study.		4	No	AZILECT® (Drug); Placebo (Drug)	University Hospital, Clermont-Ferrand	Other		Inclusion Criteria: - Drug-naïve patients with Parkinson's disease (UKPDBB criteria) - No dementia (Mattis dementia rating scale > 130; Mini Mental Sate Examination ≥26) - No depression (MADRS < 15) - Criteria of apathy from Robert et al (2009) - At least mild apathy (≥-21 to Lille Apathy Rating Scale) - Age : 35-70 y - Affiliation to social security - Agreement of patients 	Exclusion Criteria: - - Any antiparkinsonian treatment (L.dopa, dopamine agonists, MAO-B-I, amantadine, anticholinergics). Patients treated by dopamine agonists but who have stopped it more than 3 months before their inclusion can be included. - Ongoing severe psychiatric or somatic diseases - Others treatments : - antipsychotics - antidepressants and anxiolytics (exclusion if the treatment is not stable the month before inclusion) - psychostimulants (methylphenidate, adrafinil, modafinil, deanol, vitamin C, sulbutiamine, glutamic acid, aspartic acid) - any contra-indication according to SmPC - patients under guardianship - Women without efficient contraception - Person who participate to an other study			50	Anticipated	Unknown status
NCT02519036	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02519036","NCT02519036")		2015	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease		1/2	No	ISIS 443139 10 mg (Drug); ISIS 443139 30 mg (Drug); ISIS 443139 60 mg (Drug); ISIS 443139 90 mg (Drug); ISIS 443139 120 mg (Drug); Placebo (Other)	Ionis Pharmaceuticals, Inc.	Industry		Inclusion Criteria: - Diagnosed with early manifest Huntington's disease - Male or female, aged 25 to 65 years, inclusive, at the time of informed consent - Able and willing to meet all study requirements, including travel to Study Center and participation in all procedures and measurements at study visits - Have a trial partner who is reliable, competent and at least 18 years of age, is willing to accompany the participant to select trial visits and to be available to the Study Center by phone if needed - Able to tolerate MRI scans, blood draws and lumbar punctures - Reside within 4 hours travel of the Study Center Key 	Exclusion Criteria: - Clinically significant medical condition, such as severe chorea, active suicidal ideation or any other conditions which would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study - Recent treatment with another investigational drug, biological agent, or device - Prior treatment with an antisense oligonucleotide [including small interfering ribonucleic acid (siRNA)] - Any history of gene therapy or cell transplantation or any other experimental brain surgery - Presence of an implanted shunt for the drainage of cerebrospinal fluid (CSF) or an implanted central nervous system (CNS) catheter - History of post-lumbar-puncture headache of moderate or severe intensity and/or blood patch - Malignancy within 5 years of Screening, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated - Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned during the study			46	Actual	Completed
NCT03344601	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03344601","NCT03344601")		2018	PHysical Activity and Exercise Outcomes in Huntington's Disease	A Longitudinal Cohort Study With Nested Randomised Pragmatic Controlled Trial to Evaluate Physical Activity and Exercise Related Outcomes in People With Huntington's Disease		N/A	No	physical activity (Behavioral)	Cardiff University	Other		Inclusion Criteria: - Diagnosis of HD, confirmed by genetic testing - Above the age of 18 - A participant (current or newly enrolled) in the Enroll-HD study - Up to and including stage 2 disease status (TFC 7-13) 	Exclusion Criteria: - Diagnosis of juvenile onset HD - History of co-morbid neurological conditions such as multiple sclerosis or stroke - Acute orthopaedic conditions (within a month) e.g. ankle sprain or fracture - Inability or unwillingness of participant or legal guardian to give written informed consent			116	Actual	Active, not recruiting
NCT01120002	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01120002","NCT01120002")		2010	Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease			2	No	Tamibarotene (Drug); Placebo (Drug)	Osaka City University	Other		Inclusion Criteria: - Japanese patients who are diagnosed as probable Alzheimer' Disease according to NINCDS-ADRDA criteria - Diagnosed by brain diagnostic imaging (CT, MRI) within six months before the consent and no occurrence of the event after that to suggest cerebral vascular disease - Mild to Moderate Alzheimer's Disease of MMSE from 10 to 26 - Age from 55 to 80 - Treated for a minimum of 12 weeks with a stable dose of donepezil and willing to continue the same during the trial period - For women Menopause ≥ 2 years - For men contraceptive measures are required during the study and after 6 months - In principle patients should be living at their home in the presence of a caregiver who is defined as a healthy person in contact with the patient for more than 10 hours a week, could provide required information of the behavior and activities of daily living, accompany all the clinical examination, and supervise the handling and administration of the drug throughout the study period. - Patients who could take pills as a whole - Patient, caregiver and patient surrogate are able and willing to comply with study visits and procedures per protocol, understand, sign, and date the written voluntary informed consent form 	Exclusion Criteria: - Any cause of dementia not due to Alzheimer's disease - Past history of other central nervous condition or psychiatric disease - Symptom of depression and drug addiction - Impairment in the physical function by other factor than the Alzheimer's Disease - Patients who are expected to move in to care facilities during the study period - triglyceride > 400 mg/dL			50	Anticipated	Unknown status
NCT01594346	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01594346","NCT01594346")		2000	Multicenter Vitamin E Trial in Aging Persons With Down Syndrome			3	No	Alpha-Tocopherol (Drug); Sugar Pill (Drug)	New York State Institute for Basic Research	Other		Inclusion Criteria: - presence of clinically determined Down syndrome (karyotypes optional) - appropriately signed and witnessed consent form - age of 50 years or older at the start of the protocol - medically stable - medications stable more than 1 month - involvement/cooperation of informant/caregiver 	Exclusion Criteria: - medical/neurological condition (other than Alzheimer disease) associated with dementia - inability to adequately perform the Brief Praxis Test, as demonstrated by a score <20 - in the presence of dementia, modified Hachinski score > 4 at Screening Visit - major depression within 3 months - history of coagulopathy (inherited or acquired) - current use of anticoagulants - use of experimental medications within 2 months - regular use of vitamin E greater than 50 units per day during the previous 6 months - allergy to vitamin E			349	Actual	Completed
NCT00712426	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00712426","NCT00712426")		2009	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)		3	No	Creatine Monohydrate (Drug); Placebo (Drug)	Massachusetts General Hospital	Other		Inclusion Criteria: - Male or female ages 18 or older. - Clinical features of HD AND confirmatory family history of HD; OR Clinical features of HD AND CAG repeat expansion greater or equal to 36. - Stage I or II of illness (TFC greater or equal to 7). - Ambulatory and not requiring skilled nursing care at the time of enrollment. - Must be capable of providing informed consent and complying with trial procedures. - Additional inclusion criteria apply. 	Exclusion Criteria: - History of known sensitivity or intolerability to creatine monohydrate. - Exposure to any investigational drug within 30 days of randomization (Baseline visit). - Use of supplemental creatine at a dose greater than 10 grams within 30 days of randomization (Baseline visit). - Screening laboratory abnormalities that in the judgment of the investigator would jeopardize safe conduct of study. - Clinical evidence of unstable medical illness. - Clinical evidence of unstable psychiatric illness. - Additional exclusion criteria apply.			553	Actual	Terminated
NCT01844648	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01844648","NCT01844648")		2013	Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients	A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Safety and Efficacy of Tropicamide 1 mg Intra-oral Slow Dissolving Muco-adhesive Thin Films to Reduce Hypersalivation in PD Patients Manifesting Sialorrhea Complaints		2	No	NH004 tropicamide (Drug); NH004 Placebo (Drug)	NeuroHealing Pharmaceuticals Inc.	Industry		Inclusion criteria: - Patients with idiopathic Parkinson's disease, according to the UK Brain Bank criteria. - Patients complaining of drooling, with a score of at least 6 points in the SCS-PD scale. - Patients above 30 years old. - Patients with Hoehn & Yahr score between I-IV. - Male or non-pregnant female. Females of child-bearing potential will be required to have undergone a pregnancy test with negative results prior to entry to the study and agree to use contraceptive measures for the duration of the study. - Patients must have used the same antiparkinsonian medications and at the same dose for the last month. No changes in the medication for PD are expected during the study. 	Exclusion criteria: - Pregnant women. - Patients with a secondary parkinsonian syndrome, parkinsonism-plus syndromes, heredodegenerative disorders or benign parkinsonism. - Patients with a diagnosis of major depression or psychosis according to the DSM-IV. - Patients with MMSE score equal to or lower than 24. - Patients with a current diagnosis of substance abuse (DSM-IV) or history of alcohol or drug abuse in the past 3 months. - Patients with hallucinations. - Patients with a current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including hypertension that is not well-controlled, asthma, chronic obstructive pulmonary disease (COPD) and Type I diabetes. - Patients with a second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or significant ECG abnormality, including QTc ≥ 450 msec (males) or ≥ 470 msec (females), where QTc is based on Bazett's correction method. - Patient with a neoplastic disorder, which is either currently active or has been in remission for less than one year. - Patients with a history or a current diagnosis of HIV, or tests positive for Hepatitis B or C antibodies, or Hepatitis B surface antigen - Patients who have participated in a previous clinical trial within 30 days of entry into the study (screening visit) or have received treatment with any investigational compound within 30 days. - Patients with hypersensitivity to atropine or other anticholinergic drugs. - Patients who have experienced adverse effects as a result of taking anticholinergic drugs. - Patients who are receiving any anticholinergic drug or an anticholinesterase agent. - Patients who started or changed the dose of any of the following medications in the previous week: tricyclic antidepressants, monoamine oxidase-A inhibitors, antipsychotics, benzodiazepines, opioids, antihistamines, carbamazepine, NSAIDs. - Patients with significant dental/oral pathology. - Patient with any abnormality that the investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in a diagnostic laboratory test. - Patients with closed-angle Glaucoma or those at high risk of suffering it after treatment with anticholinergic agents. - Patients with Prostatic Adenoma. - In the judgment of the Clinical Investigator, the patient is likely to be non-compliant or uncooperative during the study.			30	Actual	Completed
NCT02215616	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02215616","NCT02215616")		2014	A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod	A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease		2	No	Laquinimod (Drug); Placebo (Drug)	Teva Branded Pharmaceutical Products, R&D Inc.	Industry		Inclusion Criteria: - Documentation of prior positive genetic testing for HD, or a clinical diagnosis of symptomatic HD. - Presence of 36-49 cytosine-adenosine-guanine (CAG) repeats, inclusive, in the huntingtin gene based on centralized CAG testing during screening. - Male or female between 21-55 years of age, inclusive, with an onset of HD at or after 18 years of age. - Women of child-bearing potential (women who are not post menopausal or who have undergone surgical sterilization) must practice an acceptable method of birth control for 30 days before taking the study treatment, and 2 acceptable methods of birth control during all study duration and until 30 days after the last dose of treatment was administered. - A sum of greater than (>) 5 points on the UHDRS-TMS at the screening visit. - Able and willing to provide written informed consent prior to any study related procedure being performed at the screening visit. Participants with a legal guardian should be consented according to local requirements. - Willing to provide a blood sample for genomic CAG analysis at the screening visit. - Willing and able to take oral medication and able to comply with the study specific procedures. - Ambulatory, being able to travel to the study center, and judged by the investigator as likely to be able to continue to travel for the duration of the study. - Availability and willingness of a caregiver, informant, or family member to provide input at study visits assessing Clinician's Interview-Based Impression of Change (CIBIC)-Plus, Clinical Dementia Rating - Sum of Boxes (CDR-SB), Problem Behaviors Assessment-Short form (PBA-s) and Huntington's Disease Quality of Life (HD-QoL). A caregiver is recommended to be someone who attends to the participant at least 2 to 3 times per week for at least 3 hours per occasion, and the suitability of the caregiver should be judged by the investigator. - For participants taking allowed antidepressant medication, the dosing of medication must have been kept constant for at least 30 days before baseline and must be kept constant during the study. - Additional criteria may apply, please contact the investigator for more information. 	Exclusion Criteria: - Use of immunosuppressive agents, or cytotoxic agents, including cyclophosphamide and azatioprine within 12 months prior to screening. - Previous use of laquinimod. - Use of moderate/strong inhibitors of cytochrome P450 (CYP)3A4 within 2 weeks prior to randomization. - Use of inducers of CYP3A4 within 2 weeks prior to randomization. - Pregnant or breastfeeding. - Participants with a clinically significant or unstable medical or surgical condition that may put the participant at risk when participating in the study or may influence the results of the study or affect the participant's ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG), or laboratory tests. Such conditions may include: - A major cardiovascular event (for example; myocardial infarction, acute coronary syndrome, de-compensated congestive heart failure, pulmonary embolism, coronary revascularization) that occurred prior to randomization. - Any acute pulmonary disorder. - A central nervous system (CNS) disorder other than HD that may jeopardize the participant's participation in the study, including such disorders that are demonstrated on the baseline MRI (based on local read). - A gastrointestinal disorder that may affect the absorption of study medication. - Acute or chronic renal disease including acute kidney injury (AKI). - Any form of acute or chronic liver disease. - Known human immunodeficiency virus (HIV) positive status. Participants will undergo an HIV test at screening per local requirements, if applicable. - Any malignancies, excluding basal cell carcinoma, in the 5 years prior to randomization. - Any clinically significant, abnormal, screening laboratory result which in the opinion of the investigator, affects the participant' suitability for the study or puts the participant at risk if he/she enters the study. - Unsuitable for MRI (for example; claustrophobia, metal implants). - Alcohol and/or drug abuse within the 12 months prior to screening, as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition Text Revision (DSM IV TR) criteria for substance abuse. - Participants with active suicidal ideation during the past month as measured by a most severe suicide ideation score of 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan) or 5 (Active Suicidal Ideation with Specific Plan and Intent) on the baseline screening Columbia-Suicide Severity Rating Scale (C-SSRS) or participants who answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) if the attempt or acts were performed within 1 year of screening, or participants who, in the opinion of the investigator, present a serious risk of suicide. - Participants with known intracranial neoplasms, vascular malformations, or intracranial hemorrhage. - Known drug hypersensitivity that would preclude administration of laquinimod or placebo, such as hypersensitivity to mannitol, meglumine or sodium stearyl fumarate. - Swallowing difficulties that would preclude administration of laquinimod or placebo capsules. - Treatment with any investigational product within 30 days of screening or participants planning to participate in another clinical study assessing any investigational product during the study. Participants in non-interventional and/or observational studies will not be excluded from participating in this study. - Treatment with tetrabenazine within 30 days of the study baseline visit. - Treatment with antipsychotic medication within 30 days of the study baseline visit. - Additional criteria may apply, please contact the investigator for more information			352	Actual	Completed
NCT00733642	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00733642","NCT00733642")		2008	Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease	An Open Label, Single Dose Escalation Study Of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease		1	No	PF-04360365 1 mg/kg (Biological); PF-04360365 3 mg/kg (Biological); PF-04360365 5 mg/kg (Biological); PF-04360365 10 mg/kg (Biological)	Pfizer	Industry		Inclusion Criteria: - Male or female (of non-child bearing potential) subjects ages ≥50 years of age. - Diagnosis of probable AD (of mild to moderate severity), consistent with criteria from both: NINCDS-Alzheimer's Disease and Related Disorders Association (ADRDA) and DSM-IV-TR. - MMSE score of 16-26 inclusive. - Rosen-Modified Hachinski Ischemia Score ≤4. - On a stable dose of background cholinesterase inhibitors or memantine for at least 60 days prior to dosing. 	Exclusion Criteria: - Diagnosis or history of other dementia or neurodegenerative disorders. - Diagnosis or history of clinically significant cerebrovascular disease. - Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes. - History of allergic or anaphylactic reactions.			15	Actual	Completed
NCT04188067	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT04188067","NCT04188067")		2020	TMS for the Treatment of Primary Progressive Aphasia	TMS in Primary Progressive Aphasia: Modulation of Brain Networks and Language		Early 1	No	ACTIVE rTMS (Device); SHAM rTMS (Device)	Massachusetts General Hospital	Other		Inclusion Criteria: 1. Patients, age 18-90, who carry a diagnosis of either the logopenic (lvPPA), agrammatic non-fluent (nfvPPA) or semantic (svPPA) variants of Primary Progressive Aphasia (PPA). Patients must have been observed for at least one year by a specialized clinician. 2. Patients must have at least mild to moderate language impairment. 3. Patients must be native English speakers. 4. Patients must have a study partner (e.g. spouse, sibling or adult child) who can accompany them to every study visit. 	Exclusion Criteria: 1. Any history of seizures, unexplained loss of consciousness or a first-degree family member with epilepsy. 2. Any history of significant co-occurring neurological illness unrelated to neurodegeneration associated with PPA (e.g. multiple sclerosis), or significant medical problems (e.g. poorly controlled diabetes/hypertension or cancer within 5 years). 3. Active symptoms of major depressive disorder, bipolar disorder, schizophrenia, substance use disorder or significant premorbid intellectual disability according to Diagnostic Statistical Manual (DSM-5) criteria. 4. Magnetic Resonance Imaging (MRI) evidence of significant cerebrovascular disease, hydrocephalus or the presence of a space-occupying intra-cranial mass. Contraindications to MRI or repetitive transcranial magnetic stimulation (rTMS) including: cardiac pacemaker or pacemaker wires, neurostimulators, implanted pumps, metal in the body (rods, plates, screws, shrapnel, dentures, intrauterine device), surgical aneurysm clips in the head, previous neurosurgery or cochlear implants. 5. In line with published Massachusetts General Hospital (MGH) Institutional Review Board (IRB) guidelines for rTMS, pregnancy must be ruled out by urine ß-Human Chorionic Gonadotropin if answers to screening questions suggest that pregnancy is possible and if female participants are premenopausal and of child-bearing age. Subjects will not be able to enroll if they are breastfeeding.			30	Anticipated	Not yet recruiting
NCT01998841	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01998841","NCT01998841")		2013	A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort	A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease		2	No	Crenezumab (Drug); Placebo (Drug)	Genentech, Inc.	Industry		Inclusion Criteria: - Membership in PSEN1 E280A mutation carrier kindred - Agrees to conditions of, and is willing to undergo, genetic testing (for example [e.g.], apolipoprotein E [APOE], PSEN1 E280A, and other genetic testing) - PSEN1 E280A mutation carrier or non-carrier status has been confirmed prior to or during the screening period - Mini-Mental Stage Examination (MMSE) greater than or equal to (>=) 24 for participants with less than (<) 9 years of education or MMSE >=26 for participants with 9 or more years of education - Does not meet criteria for dementia due to AD per the National Institute on Aging and the Alzheimer's Association Workgroup (McKhann et al. 2011) criteria - Does not meet criteria for mild cognitive impairment (MCI) due to AD per the National Institute on Aging and the Alzheimer's Association Workgroup (Albert et al. 2011) criteria - Adequate vision and hearing in the investigator's judgment to be able to complete testing - If female, and not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, willing to undergo pregnancy tests at protocol-specific timepoints - For women who are not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of <1 percent (%) per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, tubal ligation) during the treatment period and for at least 16 weeks after the last dose of study drug - For men with partners of childbearing potential (that is [i.e.], women who are not surgically sterile and are not postmenopausal), agreement to remain abstinent or use a condom as a method of contraception during the treatment period and for at least 8 weeks after the last dose of study drug - Study partner who agrees to participate in the study and is capable of and willing to: accompany the participant to all required visits; provide information for required telephone assessments; spend sufficient time with the participant to be familiar with his/her overall function and behavior and be able to provide adequate information about the participant including knowledge about domestic activities, hobbies, routines, social skills and basic activities of daily life; work and educational history; cognitive performance including memory abilities, language abilities, temporal and spatial orientation, judgment and problem solving; emotional and psychological state; and general health status - Participant and study partner have evidence of adequate premorbid functioning (e.g., intellectual, visual, and auditory) and are fluent in, and able to read, the language in which study assessments are administered - Willing and able to undergo neuroimaging (PET and MRI) - Serum thyroid stimulating hormone (TSH) and B12 levels within normal or expected ranges for the testing laboratory or if TSH and B12 values are out of range they are judged by the investigator not to be clinically significant. If participant is undergoing thyroid replacement therapy, TSH levels must be within normal or expected ranges for the testing laboratory or, if TSH values are out of range, they do not require any therapeutic actions (treatment or surveillance). If participant is receiving vitamin B12 injections or oral vitamin B12 therapy, B12 levels must be at or above the lower limit of normal for the testing laboratory or, if B12 values are out of range, they do not require any therapeutic actions (treatment or surveillance) - In good general health with no known co-morbidities expected to interfere with participation in the study 	Exclusion Criteria: - Significant medical, psychiatric, or neurological condition or disorder documented by history, physical, neurological, laboratory, or electrocardiogram (ECG) examination that would place the participant at undue risk in the investigator's judgment or impact the interpretation of efficacy - History of stroke. Participants with a history of transient ischemic attack may be enrolled if the event occurred >=2 years prior to screening - History of severe, clinically significant (persistent neurological deficit or structural brain damage) central nervous system trauma (e.g. cerebral contusion) - Body weight <45 or >120 kilograms (kg) - History or presence of atrial fibrillation that poses a risk for future stroke in the investigator's judgment - Clinically significant laboratory or ECG abnormalities (e.g., abnormally prolonged or shortened QTc interval) in the investigator's judgment - Current presence of bipolar disorder or other clinically significant major psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders 4th Edition Text Revision (DSM-IV-TR) or symptom (e.g., hallucinations, agitation, paranoia) that could affect the participant's ability to complete evaluations - Clinically significant depression, based in part by a Geriatric Depression Scale (short form) (15-point scale) score >9 at screening - History of seizures (excluding febrile seizures of childhood, or other isolated seizure episodes that were not due to epilepsy in the judgment of the investigator, and required at most time-limited anticonvulsant treatment, and which occurred more than 7 years prior to the screening visit) - Myocardial infarction within 2 years, congestive heart failure, atrial fibrillation, or uncontrolled hypertension - Pregnant or nursing women, or women who intend to become pregnant or to nurse infants during the conduct of this trial - Clinically significant infection within the last 30 days prior to screening - Positive urine test for drugs of abuse at screening - History of alcohol or substance dependence within the previous two years - Use of any other medications with the potential to significantly affect cognition; intermittent or short-term use of these medications may be allowed if deemed medically necessary for the treatment of a non-excluded medical condition with approval from the Medical Monitor. In addition, use of tricyclic antidepressants or benzodiazepines will be permitted if used in stable, low doses for the treatment of a non-excluded medical condition with approval from the Medical Monitor - Use of typical anti-psychotics or barbiturates - Use of non-anti-cholinergic antidepressant medications or atypical anti-psychotics unless maintained on a stable dose regimen for at least 6 weeks prior to screening - Use of any Food and Drug Administration (FDA)/Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)-approved medications for treatment of late onset Alzheimer's disease (LOAD) at screening/baseline. Cholinesterase inhibitors and/or memantine are prohibited during the study except in participants enrolled in the study that develop AD dementia - Use of anti-coagulant medication (heparinoids, heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors), or known coagulopathy or platelet count <100,000 cells/microliter, within 4 weeks of the screening visit; Anti-platelet medications (e.g., aspirin, clopidigrel, dipyridamole) are permitted if on a stable dose for 4 or more weeks prior to screening. Short-term, peri-operative use of anti-coagulants may not result in discontinuation from the study; however, any such use must be discussed with the Medical Monitor - Treatment with any biologic therapy within five half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed - Use of anti-seizure medication (except in childhood for febrile seizures or if used for non-seizure indications), anti-parkinsonian, or stimulant (e.g., methylphenidate) medications - Use of investigational drug, device, or experimental medication within 60 days (or five half-lives, whichever is longer) of the screening visit - Previous treatment with crenezumab or any other therapeutic that targets A-beta - History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins - Contraindication to MRI scan procedures or clinically significant claustrophobia that would contraindicate a brain MRI scan - Contraindication to PET scan procedures			252	Actual	Active, not recruiting
NCT03313518	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03313518","NCT03313518")		2016	Therapeutic Role of Transcranial DCS in Alzheimer	Therapeutic Role of Transcranial Direct Current Stimulation (tDCS) in Alzheimer Patients, Double Blind Placebo Controlled Clinical Trial		N/A	No	tDCS (Device); Sham tDCS (Device)	Assiut University	Other		Inclusion Criteria: - All subject were diagnosed with Probable AD according to NINCDS/ADRDA Criteria for Alzheimer's Disease. - Onset age > 60. - All 4 grandparents are of Ashkenazi Jewish origin as declared by the subject. - Subject or subject's legal representative has signed the informed consent form. 	Exclusion Criteria: - All subjects who were diagnosed with Possible AD according to NINCDS/ADRDA Criteria for Alzheimer's Disease. - Subjects who were diagnosed with dementia due to other diseases, or with AD and contribution of other disorders (Mixed dementia): - Brain CT/MRI suggesting alternative diagnoses, such as intracranial space occupying lesions, vascular lesion of the brain, white matter lesion, or hydrocephalus. - Subjects who had known carrier of a blood transmitted infectious disease or suffers from conditions in which phlebotomy is contra-indicated.			30	Actual	Completed
NCT01795859	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01795859","NCT01795859")		2013	First Time Use of SD-809 in Huntington Disease	A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease		3	No	SD-809 (Drug); Placebo (Drug)	Teva Pharmaceutical Industries	Industry		Inclusion Criteria: - Subject is at least 18 years of age or the age of majority (whichever is older) at Screening. - Subject has been diagnosed with manifest HD - Subject is able to swallow study medication whole. - Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion. - The subject has a reliable caregiver who interacts with the patient on a daily basis, oversees study drug administration, assures attendance at study visits and participates in evaluations, as required. - Subject is able to ambulate without assistance for at least 20 yards (Note: The use of assistive devices (i.e., walker, cane) is permitted during ambulation). 	Exclusion Criteria: - Subject has a serious untreated or under-treated psychiatric illness, such as depression, at Screening or Baseline. - Subject has active suicidal ideation at Screening or Baseline. - Subject has history of suicidal behavior at Screening or Baseline: - Subject has evidence for depression at Screening or Baseline. - Subject has an unstable or serious medical or psychiatric illness at Screening or Baseline. - Subject has been recently exposed to tetrabenazine. - Subject has received any of the following concomitant medications within 30 days of Screening or Baseline: - Antipsychotics - Metoclopramide - Monoamine oxidase inhibitors (MAOI) - Levodopa or dopamine agonists - Reserpine - Amantadine - Memantine - Subject has significantly impaired swallowing function at Screening. - Subject has significantly impaired speaking at Screening. - Subject requires treatment with drugs known to prolong the QT interval. - Subject has a prolonged QT interval on 12-lead ECG at Screening. - Subject has evidence of hepatic impairment at Screening. - Subject has evidence of significant renal impairment at Screening. - Subject has known allergy to any of the components of study medication. - Subject has participated in an investigational drug or device trial within 30 days (or 5 drug half-lives) of Screening, whichever is longer. - Subject is pregnant or breast-feeding at Screening or Baseline. - Subject acknowledges present use of illicit drugs at Screening. - Subject has a history of alcohol or substance abuse in the previous 12 months.			90	Actual	Completed
NCT03761849	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03761849","NCT03761849")		2019	A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease		3	No	RO7234292 (Drug); Placebo (Drug)	Hoffmann-La Roche	Industry		Inclusion Criteria: - Manifest HD diagnosis, defined as a DCL score of 4 - Independence Scale (IS) score >= 70 - Genetically confirmed disease by direct DNA testing with a CAP score >400 - Clinical assessment to ensure individual has intact functional independence at baseline to maintain self-care and core activities of daily living (ADLs). 	Exclusion Criteria: - Any serious medical condition or clinically significant laboratory, or vital sign abnormality or claustrophobia at screening that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study - Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study drug			909	Anticipated	Recruiting
NCT03515213	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03515213","NCT03515213")		2017	Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease	A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease		2	No	Fenofibrate (Drug); Placebo (Drug)	University of California, Irvine	Other		Inclusion Criteria: - An adult of either sex, ages 25-85 inclusive, - Have proficiency with written and spoken English and corrected vision or hearing to complete the cognitive testing, - Are able to give informed consent, - Have good overall health status with no known problems anticipated over the course of the trial, - Have a diagnosis of HD supported by positive gene test within the past 6 months. 	Exclusion Criteria: - Other major neurological disease [e.g., multiple sclerosis, parkinson's disease, cortical stroke, etc] - Clinically significant hepatic or renal disease, - Current or recent (< 1 month) use of dopamine blocking agents such as tetrabenazine, anticonvulsants, neuroleptics, HAART, antiemetics, and antipsychotics for any reason, - Current use of Warfarin (Coumadin). Enrollment in another investigational drug study within the prior three months.			20	Anticipated	Active, not recruiting
NCT03842969	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03842969","NCT03842969")		2019	An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies	An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease		3	No	RO7234292 (RG6042) (Drug)	Hoffmann-La Roche	Industry		Inclusion Criteria: - Prior enrollment in a Roche-sponsored or Genentech-sponsored study in HD for the RO7234292 (RG6042) development program that made provision for entry into an OLE study - For women of childbearing potential: agreement to remain abstinent or use contraceptive measures - For men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm 	Exclusion Criteria: - Withdrawal of consent from the preceding study - Permanent discontinuation of RO7234292 (RG6042) for any drug-related safety concern during the preceding study or meeting of any study treatment discontinuation criteria specified in the preceding study at the time of enrollment into this study - An ongoing, unresolved, clinically significant medical problem that in the judgment of the investigator would make it unsafe for the patient to participate in this study - Antiplatelet or anticoagulant therapy within 14 days prior to inclusion or anticipated use during the study, including, but not limited to, aspirin, clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban, and apixaban - History of bleeding diathesis or coagulopathy - Platelet count less than the lower limit of normal - Concurrent participation in any therapeutic clinical trial - Study treatment (RO7234292/RG6042) is commercially marketed in the patient's country for the patient-specific disease and is accessible to the patient - Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study drug			1050	Anticipated	Recruiting
NCT02481674	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02481674","NCT02481674")		2015	A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503)	A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503		2	No	VX15/2503 (Drug); Placebo (Drug)	Vaccinex Inc.	Industry		Inclusion Criteria Highlights: 1. Male or female and are at least greater than or equal to 21 years of age at Screening. 2. Must fulfill one of the following criteria at Screening: 1. Late prodromal HD as defined by a CAP score of greater than 200 and DCL 2 or 3. 2. Early manifest HD as defined by a TFC greater than or equal to 11. Subject must have been determined to have a clinical diagnosis of HD by the Site Investigator as defined by a DCL of 4. 3. Must fulfill both of the following criteria at Screening: 1. Have undergone genetic testing with a known CAG repeat greater than or equal to 36. 2. No features of juvenile HD (Westphal variant). 4. If female must be either surgically sterile, postmenopausal, or nonlactating and nonpregnant. Female subjects of childbearing potential must practice a highly effective method of contraception. 5. If male, must agree to use a reliable method of birth control (condoms with contraceptive foams or sexual abstinence) during the study and for 6 months after the last dose of study drug. 6. Are willing and capable of providing informed consent for study participation, CAG genotyping (all subjects). 7. Are capable of reading, writing, and communicating effectively with others. 8. Are taking stable doses of any concomitant medications (including tetrabenazine and deutetrabenazine) during the 1 month prior to the Baseline Visit, with the exception of newly prescribed anxiolytics for the use of pre-medication prior to imaging at screening, which will be permitted on a case-by-case basis. 9. Must meet all criteria required to move forward with the Randomization Authorization Flow (RAF) and be considered eligible by the RAF Reviewer. 	Exclusion Criteria Highlights: 1. Have participated in an investigational drug or device study within 30 days of the Baseline Visit, or 180 days if previous investigational drug was a MAb therapeutic, or previously participated in SIGNAL Cohort A. This does not apply to Cohort B subjects who are being offered the option to participate in the extension of Cohort B. 2. Have had previous neurosurgery for Huntington's disease or other movement disorders. 3. Are a suicide risk, as determined by meeting any of the following criteria: 1. suicide attempt within one year prior to Baseline. 2. suicidal ideation as defined by a positive response to question 5 on the C-SSRS (Baseline visit form) suicidal ideation section, within 60 days of the Baseline Visit. 3. significant risk of suicide, as judged by the site Investigator. 4. Have marked cognitive impairment with a Montreal Cognitive Assessment (MoCA) Score less than or equal to 22. 5. Have a presence of clinically significant psychosis and/or confusional states, in the opinion of the site Investigator. 6. Have clinically significant laboratory or ECG abnormalities at Screening, in the opinion of the site Investigator. 7. Have clinically relevant hematologic, hepatic, cardiac, or renal disease. 8. Have a medical history of infection with human immunodeficiency virus, hepatitis C and/or hepatitis B, or found to have an abnormality at Screening. 9. Have a history of substance abuse (based on DSMIV criteria) within the past 12 months prior to Screening. 10. If female are pregnant or breastfeeding. 11. Have a known allergy to any ingredient in the study drug. 12. Have a history of malignancy of any type within 2 years prior to Screening. A history of surgically excised non-melanoma skin cancers, and superficial bladder or prostate cancer is permitted. 13. Have a clinically significant medical, surgical, laboratory, or behavioral abnormality which in the judgment of the site Investigator makes the subject unsuitable for the study. 14. Have any significant findings not related to HD on the screening MRI which in the judgment of the site Investigator makes the subject unsuitable for the study. 15. Have any of the following conditions (which would exclude MRI participation): 1. An implant/device/condition that is contraindicated for MRI (e.g. pacemaker, severe claustrophobia, prosthetic heart valve, any metal fragments in the eyes or body--in some cases, an X-ray may be needed before an MRI scan, to ensure it is safe to enter the scanner). 2. Body habitus that would impede completion of MRI scan. (Subject weight above 158 kg should be discussed with the Medical Monitor). NOTE: If PET is done on PET-MRI all the above conditions apply for PET-MRI. 16. Are undergoing FDG-PET and have received research-related radiation exposure that exceeds institutional guidelines in the prior year if applicable. 17. Are undergoing a LP for CSF collection and have any of the following conditions: uncorrected bleeding or clotting disorders, skin infections near the site of the LP, suspicion of increased intracranial pressure, allergies to numbing medications (local anesthetics), acute spinal trauma, history of migraines. 18. Are undergoing a LP for CSF collection and taking any of the following types of anticoagulants: coumarins and indandiones, Factor Xa inhibitors, heparins, or thrombin inhibitors.			301	Actual	Active, not recruiting
NCT01760005	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01760005","NCT01760005")		2012	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.	A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease		2/3	Yes	Gantenerumab (Drug); Solanezumab (Drug); Matching Placebo (Gantenerumab) (Drug); Matching Placebo (Solanezumab) (Drug)	Washington University School of Medicine	Other		Inclusion Criteria: - Between 18-80 years of age - Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have an autosomal dominant Alzheimer's disease (ADAD) mutation in their family. - Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset for treatment arms. For Cognitive Run-In (CRI): includes participants who are younger than 15 years prior to the expected age of cognitive symptom onset, in addition to those 15 years younger and no more than 10 years older than expected or actual age of cognitive symptom onset. - Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive) - Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning - Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations. - For women of childbearing potential, if partner is not sterilized, subject must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide). - Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments. - Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion. 	Exclusion Criteria: - History or presence of brain MRI scans indicative of any other significant abnormality - Alcohol or drug dependence currently or within the past 1 year - Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan. - History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders - Anticoagulants except low dose (≤ 325 mg) aspirin. - Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months. - History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years. - Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial. - Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.			490	Anticipated	Recruiting
NCT01634360	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01634360","NCT01634360")		2004	Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations	A 48-month Open Label Multi-centered Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 in Patients With Parkinson's Disease With "Wearing Off" Motor Fluctuations and "on" Period Dyskinesias		2	No	Perampanel (Drug)	Eisai Inc.	Industry		Inclusion Criteria: - Patients enrolled in Study E2007-E044-204 and who either completed 12 weeks of study drug treatment or who withdrew from the study due to lack of efficacy. 	Exclusion Criteria: - Pregnant or lactating women. - Women of child bearing potential unless infertile (including surgically sterile) or practicing effective contraception (e.g. abstinence, IUD-intrauterine device, or barrier method plus hormonal method). These patients must also be willing to remain on their current form of contraception for the duration of the study. Postmenopausal women may be recruited but must be amenorrhoeic for at least 1 year to be considered of non-child bearing potential. - Fertile men not willing to use reliable contraception and fertile men with partners not willing to use reliable contraception. These patients and their partners must also be willing to remain using reliable contraception for the duration of the study. - Patients with a past or present history of drug or alcohol abuse. - Patients with a past (within one year) or present history of psychotic symptoms requiring antipsychotic treatment. Patients may be taking anti-depressant medication, however the dose must have been kept stable for at least 8 weeks prior to baseline visit. - Patients with unstable abnormalities of the hepatic, renal, cardiovascular, respiratory, gastro-intestinal, haematological, endocrine or metabolic systems which might complicate assessment of the tolerability of the study medication. - Patients with significantly elevated liver enzymes (abnormal bilirubin or serum transaminase levels of more than 1.5 times the upper normal limit). - Patients with current or prior treatment (within 4 weeks prior to the Baseline visit) with medication known to induce the enzyme cytochrome P450 3A4 including but not limited to; carbamazepine; dexamethasone; ethosuximide; phenobarbital; phenytoin; primidone; rifabutin; rifampicin; and St John's Wort. - Current or prior treatment (within 4 weeks prior to baseline visit) with methyldopa, budipine, reserpine or intermittent use of liquid forms of levodopa or as needed (prn) apo-morphine. - Patients with previous stereotactic surgery (e.g. pallidotomy) for Parkinson's disease or who are likely to undergo surgery for Parkinson's disease while participating in this study. - Patients receiving deep brain stimulation (DBS) or who are likely to undergo DBS for Parkinson's disease while participating in the extension study. - Patients with clinically significant cognitive impairment (mini-mental state examination (MMSE) <24 and /or fulfilling diagnostic and statistical manual of mental disorders (DSM IV) criteria for dementia due to Parkinson's disease). - Patients with conditions affecting the peripheral or central sensory system.			185	Actual	Terminated
NCT00592995	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00592995","NCT00592995")		2007	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Creatine Safety and Tolerability in Premanifest HD: PRECREST		2	No	Creatine monohydrate (Drug); Placebo (Drug)	Massachusetts General Hospital	Other		Inclusion Criteria: - Expansion positive or 50% at risk for HD and not diagnosed clinically 	Exclusion Criteria: - Unstable medical conditions Additional inclusion and exclusion criteria apply.			64	Actual	Completed
NCT03225833	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03225833","NCT03225833")		2017	Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease		1/2	No	WVE-120101 (Drug); Placebo (Drug)	Wave Life Sciences Ltd.	Industry		Inclusion Criteria: - Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion - Ambulatory, male or female patients aged ≥25 - ≤65 years - Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4 - Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13 Key 	Exclusion Criteria: - Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years. - Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 half-lives of the oligonucleotide, whichever is longer - Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy - Inability to undergo brain MRI - Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture			48	Anticipated	Recruiting
NCT02197130	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02197130","NCT02197130")		2014	Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease	A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease		2	No	PF-02545920 (Drug); PF-02545920 (Drug); Placebo (Other)	Pfizer	Industry		Inclusion Criteria: - CAG repeat equal or greater than 36; - Total motor score equal or greater than 10; - Total functional capacity equal or greater than 7. 	Exclusion Criteria: - Clinically significant neurologic disorder other than Huntington's disease; - Other severe acute psychiatric conditions, mania and/or psychosis; - History of neutropenia, and myeloproliferative disorders;			272	Actual	Completed
NCT00393562	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00393562","NCT00393562")		2006	Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease	Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease		N/A	No	modafinil (Drug); methylphenidate (Drug)	US Department of Veterans Affairs	U.S. Fed		Inclusion Criteria: - Veteran at study site 	Exclusion Criteria: - Patients unable to give consent - Diagnosis of EDS prior to diagnosis of PD - Brain injury due to trauma, CVA, tumor or anoxia			0	Actual	Withdrawn
NCT04250376	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT04250376","NCT04250376")		2017	The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias	The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias		N/A	No	Focused Transcranial Ultrasound (Device)	Neurological Associates of West Los Angeles	Other		Inclusion Criteria: - CDR stage of at least 0.5 (mild cognitive impairment) - At least one pathognomic imaging biomarker of a neurodegenerative process. 	Exclusion Criteria: - Cognitive decline clearly related to an acute illness - Subjects unable to give informed consent - Subjects with scalp rash or open wounds on the scalp (for example from treatment of squamous cell cancer) - Advanced terminal illness - Advanced kidney, pulmonary, cardiac or liver failure - Subjects who would not be able to lay down without excessive movement in a calm environment sufficiently long enough to be able to achieve sleep - Subjects with major depressive disorder - Subjects with vascular causes of dementia			100	Anticipated	Enrolling by invitation
NCT02535884	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02535884","NCT02535884")		2014	Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)	Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD): A Prospective, Randomised, Controlled, International, Multi-centre Study		N/A	No	ACTIVA® PC neurostimulator (Model 37601) (Device)	Heinrich-Heine University, Duesseldorf	Other		Inclusion Criteria: - Clinically symptomatic and genetically confirmed HD (number of CAG repeats ≥ 36) - Age ≥18 years - Moderate stage of the disease (UHDRS motor score ≥ 30) - Chorea despite best medical treatment (UHDRS chorea subscore ≥ 10) - Mattis Dementia Rating Scale ≥ 120 (or > 80% of items testable independently from motor impairment) - Patient has stable medication prior six weeks before inclusion - Signed informed consent 	Exclusion Criteria: - Juvenile HD (Westphal variant) or predominant bradykinesia - Postural instability with UHDRS retropulsion score > 2 - Severe comorbidity compromising operability and/or life expectancy and/or quality of life during the trial duration (e.g. cancer with life expectancy < 6 months, NYHA 3 and 4 rising the anaesthetic risk according to the anaesthesiologist) - Acute suicidality - Acute psychosis (symptoms within previous 6 months) - Participation in any interventional clinical trial within 2 months before screening - Cortical atrophy grade 3 - Patients with risk of coagulopathies and/or increased risk of haemorrhage - Patients with an implanted pacemaker or defibrillator - Pregnancy - lactation			50	Anticipated	Recruiting
NCT00007189	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00007189","NCT00007189")		2001	Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)	Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)		3	Yes	Naproxen Sodium (Aleve) (Drug); Celecoxib (Celebrex) (Drug)	Seattle Institute for Biomedical and Clinical Research	Other		Inclusion Criteria: - Aged 70 years or older. - Family history of parent, brother, or sister who has, or had, serious age-related memory loss, senility, dementia, or Alzheimer's disease. - Study partner available to provide information on the cognitive status of the participant and to assist with monitoring of trial medications, if needed. - Sufficient fluency in written and spoken English to participate in study visits and neuropsychological testing. - Willingness to limit use of the following for the duration of the study: vitamin E (at doses greater than 400 IU per day), non-aspirin NSAIDs, histamine H2 receptor antagonists (Tagamet, for example), corticosteroids, anti-inflammatory or analgesic doses of aspirin (greater than 81 mg per day), Ginkgo biloba extracts - Ability and intention to participate in regular study visits, in the opinion of the study physician. - Provision of informed consent. 	Exclusion Criteria: - History of peptic ulcer disease with bleeding or obstruction. - Clinically significant liver or kidney disease. - History of hypersensitivity to aspirin, ibuprofen, celecoxib, naproxen, or other NSAIDs. - Use of anti-coagulant medication. - Cognitive impairment or dementia. - Current alcohol abuse or dependence			2625	Unspecified	Completed
NCT00001626	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00001626","NCT00001626")		1997	Comparing Therapies for the Treatment of Severe Aplastic Anemia	A Randomized Trial of Antithymocyte Globulin and Cyclosporine Versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia		2	No	antithymocyte globulin (Drug); cyclophosphamide (Drug); cyclosporine (Drug)	National Heart, Lung, and Blood Institute (NHLBI)	NIH		INCLUSION CRITERIA: Severe aplastic anemia confirmed at NIH by: 1. Bone marrow cellularity less than thirty percent (excluding lymphocytes). 2. At least two of the following: Absolute neutrophil count less that 500/mm(3); Platelet count less than 20,000/mm(3); Reticulocyte count less than 60,000/mm(3). 	EXCLUSION CRITERIA: Serum creatinine greater than to 2.5 mg/dl. Cardiac ejection fraction less than 45% by MUGA. Underlying carcinoma (except local cervical, basal cell, squamous cell or melanoma). Current pregnancy or unwilling to take oral contraceptives. Diagnosis of Fanconi anemia or other congenital bone marrow failure syndromes. Evidence of a clonal disorder on cytogenetics. HIV positivity. Inability to understand the investigational nature of the study. Patients who are moribund or have hepatic, renal, cardiac, metabolic or other concurrent diseases of such severity that death within 7-10 days is likely. Previous treatment with ATG, or cyclophosphamide.			33	Actual	Completed
NCT02336633	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02336633","NCT02336633")		2015	Resveratrol and Huntington Disease	Metabolic Intervention Using Resveratrol in Patients With Huntington Disease		N/A	No	Resveratrol (Dietary Supplement); Placebo (Other)	Assistance Publique - Hôpitaux de Paris	Other		Inclusion criteria : - Positive genetic test with CAG repeat length > or = 39 in HTT gene - At least 18 years of age - Signature of the informed consent - Covered by social security - UHDRS score between 5 and 40 (both included) - Ability to undergo MRI scanning 	Exclusion criteria : - Hypersensitivity to resveratrol or to one of its excipients (gelatin and glycerin) - Tetrabenazine treatment - Neuroleptic treatments other than olanzapine at small doses (≤10 mg) and Abilify® (≤15mg) - VKA treatment (Previscan®, Sintron®, Coumadine®) - NACO treatment (Pradaxa®, Xarelto®, Eliquis®) - Additional psychiatric or neurological conditions - Severe head injury - Participation in another therapeutic trial (3 months exclusion period) - Pregnancy and breastfeeding - Inability to understand information about the protocol - Persons deprived of their liberty by judicial or administrative decision - Adult subject under legal protection or unable to consent.			102	Actual	Completed
NCT02655614	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02655614","NCT02655614")		2016	A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis	A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis		1	No	GDC-0134 (Drug); Placebo (Drug); Rabeprazole (Drug); Midazolam (Drug); Caffeine (Drug)	Genentech, Inc.	Industry		Inclusion Criteria: - Male or female participants with a diagnosis of possible, laboratory-supported probable, probable, or definite ALS according to modified El Escorial criteria - Upright forced vital capacity of at least 50 percent (%) - Ability to fast from food for 8 hours prior to dosing and 2 hours after dosing 	Exclusion Criteria: - Currently taking riluzole unless on a stable dose for the 3 months prior to Day -1 and without current liver enzyme or liver function abnormalities - Currently taking edaravone unless after completion of at least the second 14-day drug-treatment period, as long as Day 1 occurs during a drug-free period at least 24 hours after the last edaravone dose and at least 5 days prior to the first dose of the next cycle - Positive for hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus (HIV) antibody - Clinically significant thrombocytopenia - Currently taking nutritional/herbal supplements, except for over-the-counter vitamins that are within Recommended Dietary Allowance (RDA), unless discontinued at least 7 days prior to Day −1, except upon approval of both the investigator and Sponsor - For participants participating in a designated drug-drug interaction (DDI) cohort in the MAD stage of the study, who require midazolam/caffeine administration: known allergy, religious prohibition, or other condition limiting midazolam or caffeine administration			54	Actual	Active, not recruiting
NCT03225846	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03225846","NCT03225846")		2017	Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease		1/2	No	WVE-120102 (Drug); Placebo (Drug)	Wave Life Sciences Ltd.	Industry		Inclusion Criteria: - Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion - Ambulatory, male or female patients aged ≥25 - ≤65 years - Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4 - Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13 Key 	Exclusion Criteria: - Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years - Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 halflives of the oligonucleotide, whichever is longer - Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy - Inability to undergo brain MRI - Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture			60	Anticipated	Recruiting
NCT00592995	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00592995","NCT00592995")		2007	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Creatine Safety and Tolerability in Premanifest HD: PRECREST		2	No	Creatine monohydrate (Drug); Placebo (Drug)	Massachusetts General Hospital	Other		Inclusion Criteria: - Expansion positive or 50% at risk for HD and not diagnosed clinically 	Exclusion Criteria: - Unstable medical conditions Additional inclusion and exclusion criteria apply.			64	Actual	Completed
NCT00013650	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00013650","NCT00013650")		2001	Effects of an Anti-Inflammatory Drug in Alzheimer's Disease	Pilot Study of Immunomodulatory Versus Antiinflammatory Therapy in Alzheimer's Disease		1	No	Cyclophosphamate (Drug)	National Institute of Mental Health (NIMH)	NIH		INCLUSION CRITERIA: Subjects must have a diagnosis of probable Alzheimer's disease according to DSM-IV and NINDS criteria. Subjects must have mild-moderate severity of dementia according to the Clinical Dementia Rating Scale at the time of study. They must also have the ability to assign a DPA or have already assigned a DPA and give informed consent for this medication trial and be willing to undergo repeat lumbar punctures for the assessment of cerebrospinal fluid. 	EXCLUSION CRITERIA: Severe dementia (CDR score greater than 2). Diagnosis of probable vascular dementia. Inability to give assent for participation or designate a durable power of attorney. Medication history of cytotoxic drug therapy for more than 2 weeks during the 10 weeks prior to study entry, for more than 10 weeks at any time, or for anytime during the 30 day period prior to study entry. Recent use of continuous (more than 3 doses per week) nonsteroidal medication (at least one month before entry). Low dose aspirin will not be considered as continuous nonsteroidal anti-inflammatory medication. Known hypersensitivity to CY, aspirin or any nonsteroidal medication. Current use of allopurinol, rifampin, methotrexate or warfarin. Inflammatory conditions (such as SLE, autoimmune disease, etc.) which could respond to medications given in the medication protocol. Medical conditions including: active or chronic infection requiring antimicrobial therapy, serious viral infection (hepatitis, herpes zoster), a single functioning kidney, renal insufficiency (less than one third of normal GFR), significant hepatic dysfunction, pre-existent malignancy, insulin-treated diabetes mellitus, severe benign prostatic hypertrophy, immunosuppression, myelosuppression, lymphopenia, severe pulmonary dysfunction, history of gastrointestinal ulceration active within the last 5 years, history of gastrointestinal bleeding or perforation, or severe cardiac dysfunction.			60	Unspecified	Completed
NCT03342053	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03342053","NCT03342053")		2017	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)	An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)		2	No	RO7234292 (RG6042) (Drug)	Hoffmann-La Roche	Industry		Inclusion Criteria: - Must have completed dosing in ISIS 443139-CS1 Key 	Exclusion Criteria: - Any new condition or worsening of existing condition that could make the patient unsuitable for participation or interfere with the patient participating in and/or completing the study			46	Actual	Completed
NCT01806857	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01806857","NCT01806857")		2013	Clinical Trial Nuedexta in Subjects With ALS	The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)		2	No	Nuedexta (Drug); Matching Placebo (Drug)	Center for Neurologic Study, La Jolla, California,	Other		Inclusion Criteria: - ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria - Age 18 years or older - Exhibits bulbar dysfunction manifested by dysarthria and/or dysphagia, according to PI judgment, exhibits a score of 55 or above on the CNS-Bulbar Function Scale - Capable of providing informed consent and following trial procedures - Geographic accessibility to the site - Women must not be able to become pregnant for the duration of the study and must be willing to be on two contraceptive therapies - Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the screening visit - Must be able to swallow capsules throughout the course of the study, according to PI judgment - Subjects must not have taken riluzole for at least 30 days or be on a 50mg BID dose of riluzole for at least 30 days prior to randomization (subjects how have never taken riluzole are permitted in the study) - Subjects taking anti-sialorrhea medication(s) must be on a stable dose for at least 30 days prior to randomization (anti-sialorrhea naïve subjects are permitted in the study) - Must be able to safely swallow at least 30 milliliters (mLs) of water for the water swallowing test 	Exclusion Criteria: - Prior use of Nuedexta® - Current use of dextromethorphan, quinidine, quinine, mefloquine or opioids - History of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions - History of known sensitivity or intolerability to dextromethorphan - Use of an mono amine oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI - Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure - Complete atrioventricular (AV) block without implanted pacemaker, or subjects at high risk of complete AV block - Concomitant use with drugs that both prolong QT interval and are metabolized by cytochrome P 2D6 (CYP2D6) (i.e., thioridazine or pimozide) - Exposure to any other experimental agent (off-label use or investigational) within 30 days prior to Baseline Visit - Invasive ventilator dependence, such as tracheostomy - Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia, according to PI judgment - Placement and/or usage of feeding tube - Pregnant women or women currently breastfeeding - Unable to turn diaphragm pacing device off during swallowing tests - Salivatory Botox within 90 days (3 months) of screening - Salivatory radiation within 180 days (6 months) of screening			90	Actual	Completed
NCT01476306	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT01476306","NCT01476306")		2011	Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study	Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study		N/A	No	Telemedicine (Other); Usual care (Other)	Johns Hopkins University	Other		Inclusion Criteria: - The principal eligibility criteria for participants are the following: age greater than 30, clinical diagnosis of idiopathic Parkinsonism, ability to converse in English, ability and willingness to provide informed consent and complete study requirements, and access to a computer with broadband internet. 	Exclusion Criteria: - The main exclusion criterion is a condition (e.g., prominent psychosis) that in the investigator's judgment would preclude participation in a telemedicine visit. Participants may identify a principal caregiver for optional participation in the study.			20	Actual	Completed
NCT02509793	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02509793","NCT02509793")		2018	A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)	A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)		4	No	Tetrabenazine (Drug)	William Ondo, MD	Other		Inclusion Criteria: - For HUntington's Disease (HD) patients only--Definite HD as indicated by positive gene testing or typical symptoms in the context of family history of HD. - A moderate degree of impulsivity as measured by the Barrat Impulsivity Scale (BIS). (>65) - Must be symptomatic in the opinion of the investigator. Standard clinical criteria for symptomatic HD will be employed, any motor signs c/w HD, usually chorea. - Patient is cognitively alert and able to answer/understand. 	Exclusion Criteria: - Patient requires the assistance of another person to walk, or is non-ambulatory. - Patient is severely impaired cognitively. - Patients taking neuroleptic (dopamine blocking) medications within the past 14 days. - patient is actively suicidal, has untreated or inadequately treated depression, has impaired hepatic function, is taking MAO inhibitors or is taking reserpine or has been off of reserpine for less than 20 days			20	Anticipated	Recruiting
NCT02453061	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02453061","NCT02453061")		2015	A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease	A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease		2	No	Triheptanoin oil (Drug); Placebo (Drug)	Institut National de la Santé Et de la Recherche Médicale, France	Other		Inclusion Criteria: - Positive genetic test with CAG repeat length ≥39 in HTT gene - At least 18 years of age - Signature of informed consent - Covered by social security - UHDRS score between 5 and 40 - Ability to undergo MRI scanning - BMI between 18 and 30 	Exclusion Criteria: - Hypersensitivity to triheptanoin or to one of its excipients - Additional major comorbidities - History of severe head injury - Participation in another therapeutic trial (3 month exclusion period) - For women of childbearing age, the absence of two forms of effective contraception (with the exception of those who are abstinent) - Pregnancy or breastfeeding - Inability to understand information about the protocol - Persons deprived of their liberty by judicial or administrative decision - Adult subject under legal protection or unable to consent - Treatment with tetrabenazine			100	Actual	Active, not recruiting
NCT02006472	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02006472","NCT02006472")		2014	A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease	A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease		2	No	Pridopidine (Drug); Placebo (Other)	Prilenia	Industry		Inclusion Criteria: - Diagnosis of HD based on the presence of >/= 36 CAG repeats - Male or female age ≥21 years, with an onset of HD after 18 years' old. - Females of child bearing potential have to be compliant in using adequate birth control throughout the duration of the study - Body weight ≥50 kg - Sum of >/= 25 points on the UHDRS-TMS and UHDRS Independence Score below 90% - Able and willing to provide written informed consent prior to any study related procedure. - Willing to provide a blood sample for genetic analyses - Willing and able to take oral medication and able to comply with the study specific procedures. - Ambulatory, being able to travel to the study centre, and judged by the investigator as likely to be able to continue to travel for the duration of the study. - Availability and willingness of a caregiver, informant or family member to accompany the patient to the clinic at study, and the suitability of the caregiver should be judged by the investigator. - Other criteria apply, please contact the investigator for more information. 	Exclusion Criteria: - Patients with clinically significant heart disease at the screening visit - Treatment with tetrabenazine within 6 weeks of study screening - Patients with a history of epilepsy or of seizures within the last 5 years - Have other serious medical illnesses in the opinion of the investigator may put the patient at risk when participating in the study or may influence the results of the study or affect the patient's ability to take part in the study - Patients receiving medications (within the last 6 weeks prior to screening) that have been proven to prolong QT interval or who may require such medications during the course of the study such as but not limited to non allowed anti psychotic medications, tricyclic antidepressants and/or Class I antiarrhythmics - Patients receiving medications (within the last 6 weeks prior to screening) that are metabolized by CYP2D6 and have the potential of reducing seizure threshold - Other criteria apply, please contact the investigator for more information			408	Actual	Completed
NCT03189680	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03189680","NCT03189680")		2015	Agility Training in Parkinson's Disease	A High-Intensity Multi-Component Agility Intervention Improves Parkinson's Patients' Clinical and Motor Symptoms		N/A	Yes	Exercise therapy (Other)	Somogy Megyei Kaposi Mór Teaching Hospital	Other		Inclusion Criteria: - Parkinson's disease - Hoenh Yahr scale of 2-3 - Instability problem 	Exclusion Criteria: - Severe heart problems - Severe demeanor - Alcoholism - Drug problems			3	Actual	Unknown status
NCT02008357	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02008357","NCT02008357")		2014	Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss	Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)		3	No	Placebo (Drug); Solanezumab (Drug)	Eli Lilly and Company	Industry		Inclusion Criteria: - Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30 - Has a global Clinical Dementia Rating (CDR) scale score at screening of 0 - Has a Logical Memory II score at screening of 6 to 18 - Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain amyloid pathology at screening - Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication) 	Exclusion Criteria: - Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline - Lacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded - Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study - Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness - Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment - Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis) - Is clinically judged by the investigator to be at serious risk for suicide - Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM) - Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM Open-Label Inclusion Criteria: - All participants who complete the placebo-controlled period will be allowed to continue into the open-label period			1150	Anticipated	Active, not recruiting
NCT03787758	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03787758","NCT03787758")		2019	A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B	A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease		1	No	SAGE-718 (Drug)	Sage Therapeutics	Industry		Inclusion Criteria: 1. Subject is positive for mutant HTT (documented CAG repeats ≥ 40 units). 2. Subject has a body weight ≥50 kg and body mass index ≥18.0 and ≤30.0 kg/m2 at screening. 	Exclusion Criteria: 1. Subject has any clinically significant abnormal finding on the physical exam at screening or admission. 2. Subject has a history or presence of a neurologic disease or condition (other than Huntington's disease), including but not limited to severe chorea, epilepsy, closed head trauma with clinically significant sequelae, or a prior seizure. 3. Subject has a family history of epilepsy. 4. Subject has a positive screening test for alcohol or drugs of abuse (including marijuana) at screening or admission.			6	Actual	Completed
NCT03172117	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03172117","NCT03172117")		2017	Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.	Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.		1/2	No	human umbilical cord blood derived mesenchymal stem cells (Biological); Normal saline 2mL (Other)	Medipost Co Ltd.	Industry		Inclusion Criteria: - Assessment of safety and exploratory treatment efficacy in subjects who were enrolled and completed phase 1/2a clinical trial of NEUROSTEM®. - Subjects who have been treated with either NEUROSTEM® or placebo at least 12 months ago. - Subjects who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial (in case it is difficult for the participant to sign, the consent of the legal representative) 	Exclusion Criteria: - Subjects who were not enrolled in phase 1/2a clinical trial of Neurostem® for assessing safety and exploratory treatment efficacy - Other subjects, excluding those listed above, who were deemed unsuitable by the PI			45	Anticipated	Recruiting
NCT04172792	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT04172792","NCT04172792")		2019	Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS)	Safety and Tolerability of Fat-rich vs. Carbohydrate-rich High-caloric Food Supplements in Patients With Amyotrophic Lateral Sclerosis (ALS)		1	No	high-caloric fatty diet (Dietary Supplement); ultra-high-caloric fatty diet (Dietary Supplement); ultra-high-caloric carbohydrate-rich diet (Dietary Supplement)	Albert Christian Ludolph, Prof.	Other		Inclusion Criteria: - Diagnosis of Amyotrophic Lateral Sclerosis (ALS) according to the revised version of the El Escorial criteria (Ludolph et al. 2015) - Slope of ALS Functional Rating Scale Revised (ALSFRS-R) of >0.25 points per month at baseline visit based on the formula (48 - score at baseline visit) / (time between date of first symptom and baseline visit) - stable on standard therapy riluzole (100 mg/day) for at least 4 weeks - capable of thoroughly understanding all information given and giving full informed consent according to good clinical practice (GCP) 	Exclusion Criteria: - already taking any dietary supplements - participation in another clinical trial within the preceding 8 weeks - tracheostomy or assisted ventilation of any type which exceeds 23 hours per day - pregnancy or breast-feeding females			64	Anticipated	Recruiting
NCT02781454	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02781454","NCT02781454")		2016	Mexiletine in Sporadic Amyotrophic Lateral Sclerosis	Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS)		2	No	Mexiletine (Drug); Placebo (Drug)	University of Washington	Other		Inclusion Criteria: 1. Sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite ALS as defined by revised El Escorial criteria. 2. Age 18 years or older. 3. Symptom onset of weakness or spasticity due to ALS ≤ 60 months prior to Screening Visit. 4. Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the screening visit. 5. Must be able to swallow capsules throughout the course of the study, according to Site Investigator judgment. 6. Capable of providing informed consent and following trial procedures. 7. For TMS: a resting motor threshold defined as 50% of pulses eliciting a motor evoked potential (MEP) of amplitude ≥ 50 µV. 8. For TTNCS: median Compound Muscle Action Potential (CMAP) ≥ 1.5 mV. 9. Subjects must not have taken riluzole for at least 30 days or be on a stable dose of riluzole for at least 30 days prior to the Screening Visit and continue on the stable dose throughout the course of the study (riluzole-naïve subjects are permitted in the study). 10. Subjects must not have taken medication for muscle cramping such as cyclobenzaprine, baclofen, carisoprodol, or methocarbamol, for at least 30 days prior to screening or be on a stable dose for at least 60 days prior to screening. 11. Geographic accessibility to the site. 12. Women must not become pregnant for the duration of the study and must be willing to use two contraceptive therapies and have a negative pregnancy test throughout the course of the study. 13. Use of medications known to affect the neurophysiology measures in the study must be scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose for 30 days prior to the Screening Visit, and there must be no reason to believe that a subsequent change would be necessary during the course of the study. These medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamines) and anti-cholinergics. 	Exclusion Criteria: 1. Invasive ventilator dependence, such as tracheostomy. 2. Creatinine level greater than 1.5 mg/dL at screening. 3. Serum Glutamic-Oxaloacetic (SGOT/AST) / Serum Glutamic-Pyruvic (SGPT/ALT) greater than 3 times the upper limit of normal at screening. 4. History of known sensitivity or intolerability to mexiletine or lidocaine. 5. Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia. 6. Clinically significant conduction abnormalities on electrocardiogram or a known history of cardiac arrhythmia. 7. Known history of epilepsy. 8. Known history of congestive heart failure (CHF) or history of myocardial infarction within the past 24 months. 9. Use of mexiletine for 30 days prior to Screening Visit. 10. Exposure to any other experimental agent (off-label use or investigational) including high dose creatine (>10 grams a day) within 30 days prior to Screening Visit. 11. Metal in the head and neck region, cardiac pacemaker or brain stimulator, cochlear implants, implanted infusion device or personal history of epilepsy. 12. Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine. 13. Pregnant women or women currently breastfeeding. 14. Placement of Diaphragm Pacing System (DPS) device < 60 days prior to Screening Visit. 15. Planned DPS device implantation during study participation			20	Actual	Completed
NCT00514774	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00514774","NCT00514774")		2007	Ursodiol in Huntington's Disease	Ursodiol in Huntington's Disease		1	No	ursodiol (Drug); placebo (Drug)	Oregon Health and Science University	Other		Inclusion Criteria: - All subjects will be age 18 or older - All subjects will have manifest Huntington disease determined by clinical exam plus either documented prior DNA testing for the HD gene or a documented family history of the disease 	Exclusion Criteria: - Subjects taking oral contraceptives, cholestyramine, colestipol, or aluminum-based antacids will be excluded - Subjects with known allergy or other contraindication to the study drug will be excluded - Subjects with bleeding diathesis, or on coumadin or mandatory aspirin will be excluded - Subjects with unstable medical or psychiatric illness will be excluded - Subjects with clinically significant lab / EKG abnormalities at screening will be excluded - Subjects who are currently pregnant or breastfeeding will be excluded			21	Anticipated	Unknown status
NCT03575676	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT03575676","NCT03575676")		2018	Efficacy and Safety of SOM3355 in Huntington's Disease Chorea	Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements.		2	No	SOM3355 100mg BID (Drug); SOM3355 200mg BID (Drug); Placebo BID (Drug)	SOM Biotech SL	Industry		Inclusion Criteria: - Subject is at least 18 years of age at time of consent. - Diagnosis of HD definite by a movement disorders expert and confirmed by a number of HTT gene CAG repeats equal or greater than 36. - Female of child bearing potential (FCBP) and non-vasectomized male agree to practice appropriate methods of birth control. - Ability to walk independently or with minimal assistance. - UHDRS TMC score equal or greater than 8. - UHDRS TFC equal or greater than 4. - Subject has provided written informed consent or through his/her legally authorized representative. 	Exclusion Criteria: - Onset of HD symptoms prior to age 18 (Juvenile forms of HD). - Non-ambulatory patients. - A past medical history of clinically significant ECG abnormalities or a family history (grandparents, parents and siblings) of a prolonged QT-interval syndrome. - Pregnant or breastfeeding female patients, including those planning to conceive during the period of the trial. - Patients with psychiatric symptoms, or other impairments, that would interfere with their full compliance with the Investigator instructions and testing, unless there is an identified caregiver to support the patient. - Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The Investigator should make this determination in consideration of the subject's medical history and/or clinical laboratory test results at screening and baseline. - Known allergy/sensitivity/intolerance to the study drugs or their excipients. - Any significant laboratory results which, in the Investigator's opinion, would not be compatible with study participation or represent a risk for the subject while in the study. - Prescribed anti-hypertensive medication, tetrabenazine, deutetrabenazine or valbenazine within 15 days prior starting the investigational treatment. - Excluded concomitant medications: any anti-hypertensive medication, tetrabenazine, deutetrabenazine or valbenazine, all typical neuroleptics and all MAO inhibitors - Subject has a history of alcohol or substance abuse in the previous 12 months. - Patients with diabetic ketoacidosis or metabolic acidosis. - Patients with cardiogenic shock, congestive heart failure, pulmonary hypertension due to right-sided heart failure, severe sinus bradycardia, atrioventricular block (grades II and III) or sinoatrial block. - Subject has participated in an investigational drug or device trial within 30 days prior starting the investigational treatment.			32	Actual	Completed
NCT00921128	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT00921128","NCT00921128")		2009	Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease	Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease		1	No	Muscimol (Drug)	National Institute of Neurological Disorders and Stroke (NINDS)	NIH		INCLUSION CRITERIA: Diagnosed with idiopathic PD by UK criteria: Bradykinesia: At least one of the following: 1. Muscular rigidity 2. 4-6 Hz resting tremor 3. Postural instability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction Three or more required in addition to above for the diagnosis of idiopathic PD: 1. Unilateral onset 2. Rest tremor present 3. Progressive disorder 4. Persistent asymmetry affecting side of onset most 5. Excellent response (70-100%) to levodopa 6. Severe levodopa-induced chorea 7. Levodopa response for 5 years or more 8. Clinical course of ten years or more The above clinical features must not be due to trauma, brain tumor, infection, cerebrovascular disease, other known neurological disease (e.g., multiple system atrophy, progressive supranuclear palsy, striatonigral degeneration, Huntington s disease, Wilson s disease, hydrocephalus) or due to known drugs, chemicals or toxicants. Disability present despite optimal antiparkinsonian medication therapy. Unequivocal responsiveness to levodopa, based on the single-dose levodopa test (as described in the CAPIT and CAPSIT guidelines). In addition to a 33% or greater improvement in one of the timed tasks, a 30% or greater improvement in the UPDRS total motor score will be required to establish unequivocal responsiveness to levodopa. Patients must demonstrate at least 6 hours of non-on time and medication side-effects such as levodopa-induced dyskinesias or motor fluctuations. Neuropsychological evaluation does not indicate substantial depression or cognitive dysfunction. Able to provide proper Informed Consent. 	EXCLUSION CRITERIA: Presence of prominent oculomotor palsy, cerebellar signs, vocal cord paresis, orthostatic hypotension (> 20 mm Hg drop on standing), pyramidal tract signs or amyotrophy. Presence of dementia (Clinical Dementia Rating Scale score > 1.0 or Mini Mental Status Examination Score < 25). Presence or history of psychosis, including if induced by anti-PD medications. Presence of untreated or suboptimally treated depression (Hamilton Depression Scale score >10) or a history of a serious mood disorder (for example, requiring psychiatric hospitalization or a prior suicide attempt). Presence of substance (drug, alcohol) abuse. Presence of hypointensity in the striatum on T2-weighted MR-imaging. Contraindication to MR-imaging and/or gadolinium. Coagulopathy, anticoagulant therapy, low platelet count, or inability to temporarily stop any antithrombotic medication. Prior brain surgery, including gene therapy, radiofrequency ablation or deep brain stimulation. Male or female with reproductive capacity who is unwilling to use contraception throughout the study. History of stroke or poorly controlled cardiovascular disease. Uncontrolled hypertension or diabetes or any other acute or chronic medical condition that would increase the risks of a neurosurgical procedure. Clinically active infection, including acute or chronic scalp infection. Received investigational agent within 12 weeks prior to screening. Unable to comply with the procedures of the protocol, including frequent and prolonged follow-up. Baseline hematology, chemistry or coagulation values out of normal range unless not clinically significant with respect to surgery.			0	Actual	Withdrawn
NCT02346708	=HYPERLINK("https://clinicaltrials.gov/ct2/show/NCT02346708","NCT02346708")		2014	Cognitive Dysfunction in Parkinson's Disease	Cortical Physiology as a Therapeutic Target in Parkinson's Disease Related Dementia and Cognitive Dysfunction		N/A	No	Real TMS (Device); Sham TMS (Device)	University of Colorado, Denver	Other		Inclusion Criteria: - Diagnosis of probable PD (using United Kingdom Brain Bank criteria) - Diagnosis of mild cognitive impairment - No unstable medical condition 	Exclusion Criteria: - Features suggestive of other causes of Parkinsonism or other neurological disorders - Prior deep brain stimulation (DBS) or ablation surgery - Evidence for active depression or Hospital Anxiety and Depression Scale (HADS) score greater than or equal to 11 - Motor symptoms expected to interfere with scanning (e.g. sever tremor) - Contraindications to TMS, MEG, or MRI such as pregnancy, pacemaker, unstable cardiac disease, skull lesion, claustrophobia, history of epilepsy, or on medications known to lower seizure threshold - Implanted electronic devices or metal			150	Anticipated	Active, not recruiting
